The Wilms Tumour Gene WT1 in Leukaemia

References

• Call K.M., Glaser T., Ito C.Y., Buckler A.J., Pelletier J., Haber D.A., Rose E.A., Kral A., Yeger H., Lewis W.H., Jones C., Housman D.E. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms tumor locus. Cell 1990; 60: 509–520
   PubMed Web of Science ®Google Scholar
• Bickmore W.A., Oghene K., Little M.H., Seawright A., Van-Heyningen V., Hastie N.D. Modulation of DNA binding specificity by alternative splicing of the Wilms tumor wt1 gene transcript. Science 1992; 257: 235–237
   PubMed Web of Science ®Google Scholar
• Phelan S.A., Lindberg C., Call K.M. Wilms tumor gene, WT1, mRNA is down-regulated during induction of erythroid and megakaryocytic differentiation of K562 cells. Cell Growth Differ 1994; 5: 677–686
   PubMedGoogle Scholar
• Sekiya M., Adachi M., Hinoda Y., Imai K., Yachi A. Downregulation of Wilms' tumor gene (wt1) during myelomonocytic differentiation in HL60 cells. Blood 1994; 83: 1876–1882
   PubMed Web of Science ®Google Scholar
• Kudoh T., Ishidate T., Nakamura T., Akiyama T. Constitutive expression of the Wilms tumor suppressor gene WT1 in F9 embryonal carcinoma cells induces apototic cell death in response to retinoic acid. Oncogene 1996; 13: 1431–1439
   PubMed Web of Science ®Google Scholar
• Haber D.A., Sohn R.L., Buckler A.J., Pelletier J., Call K.M., Housman D.E. Alternative splicing and genomic structure of the Wilms tumor gene. WTL Proc Natl Acad Sci U S A 1991; 88: 9618–9622
   PubMed Web of Science ®Google Scholar
• Brenner B., Wildhardt G., Schneider S., Royer-Pokora B. RNA polymerase chain reaction detects different levels of four alternatively spliced WT1 transcripts in Wilms tumors. Oncogene 1992; 7: 1431–1433
   PubMed Web of Science ®Google Scholar
• Sharma P.M., Bowman M., Madden S.L., Rauscher F.J., Sukumar S. RNA editing in the Wilms tumor susceptibility gene. WT1 Genes Dev 1994; 8: 720–731
   PubMed Web of Science ®Google Scholar
• Bruening W., Pelletier J. A non-AUG translational initiation event generates novel WT1 isoforms. J-Biol-Chem 1996; 271: 8646–8654
   PubMed Web of Science ®Google Scholar
• Mundlos S., Pelletier J., Darveau A., Bachmann M., Winterpacht A., Zabel B. Nuclear localization of the protein encoded by the Wilms tumor gene WT1 in embryonic and adult tissues. Development 1993; 119: 1329–1341
   PubMed Web of Science ®Google Scholar
• Telerman A., Dodemont H., Degraef C., Galand P., Bauwens S., Van-Oostveldt P., Amson R.B. Identification of the cellular protein encoded by the human Wilms tumor (WT1) gene. Oncogene 1992; 7: 2545–2548
   PubMed Web of Science ®Google Scholar
• Menssen H.D., Renkl H.J., Rodeck U., Maurer J., Notter M., Schwartz S., Reinhardt R., Thiel E. Presence of Wilms tumor gene (WT1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias. Leukemia 1995; 9: 1060–1067
   PubMed Web of Science ®Google Scholar
• Larsson S.H., Charlieu J.P., Miyagawa K., Engelkamp D., Rassoulzadegan M., Ross A., Cuzin F., Van-Heyningen V., Hastie N.D. Subnuclear localization of WT1 in splicing or transcription factor domains is regulated by alternative splicing. Cell 1995; 81: 391–401
   PubMed Web of Science ®Google Scholar
• Caricasole A., Duarte A., Larsson S.H., Hastie N.D., Little M., Holmes G., Todorov I., Ward A. RNA binding by the Wilms tumor suppressor zinc finger proteins. Proc. Natl Acad. Sci. USA 1996; 93: 7562–7566
   PubMed Web of Science ®Google Scholar
• Pritchard-Jones K., Fleming S., Davidson D., Bickmore W., Porteous D., Gosden C., Bard J., Buckler A., Pelletier J., Housman D. The candidate Wilms tumour gene is involved in genitourinary development. Nature 1990; 346: 194–197
   PubMed Web of Science ®Google Scholar
• Ton C.C., Hirvonen H., Miwa H., Weil M.M., Monaghan P., Jordan T., Van Heyningen V., Hastie N.D., Meijers-Heijboer H., Drechsler M. Positional cloning and characterization of a paired box- and homebox-containing gene from the aniridia region. Cell 1991; 67: 1059–1074
   PubMed Web of Science ®Google Scholar
• Pelletier J., Bruening W., Kashtan C.E., Mauer S.M., Manivel J.C., Striegel J.E., Houghton D.C., Junien C., Habib R., Fouser L. Germline mutations in the Wilms tumor suppressor gene are associated with abnormal urogenital development in Denys-Drash syndrome. Cell 1991; 67: 437–447
   PubMed Web of Science ®Google Scholar
• Bruening W., Bardeesy N., Silverman B.L., Cohn R.A., Machin G.A., Aronson A.J., Housman D., Pelletier J. Germline intronic and exonic mutations in the Wilms tumour gene (WT1) affecting urogenital development. Nat Genet 1992; 1: 144–148
   PubMed Web of Science ®Google Scholar
• Konig A., Jakubiczka S., Wieacker P., Schlosser H.W., Gessler M. Further evidence that imbalance of WT1 isoforms may be involved in Denys-Drash syndrome. Hum Mol Genet 1993; 2: 1967–1968
   PubMed Web of Science ®Google Scholar
• Coppes M.J., Liefers G.J., Higuchi M., Zinn A.B., Balfe J.W., Williams B.R. Inherited WT1 mutation in Denys-Drash syndrome. Cancer Res 1992; 52: 6125–6128
   PubMed Web of Science ®Google Scholar
• Pelletier J., Bruening W., Li F.P., Haber D.A., Glaser T., Housman D.E. WT1 mutations contribute to abnormal genital system development and hereditary Wilms tumour. Nature 1991; 353: 431–434
   PubMed Web of Science ®Google Scholar
• Kreidberg J.A., Sariola H., Loring J.M., Maeda M., Pelletier J., Housman D., Jaenisch R. WT-1 is required for early kidney development. Cell 1993; 74: 679–691
   PubMed Web of Science ®Google Scholar
• Kikuchi H., Akasaka Y., Kurosawa Y., Yoneyama H., Kato S., Hata J. A critical mutation in both WT1 alleles is not sufficient to cause Wilms tumor. Febs Lett 1995; 360: 26–28
   PubMed Web of Science ®Google Scholar
• Sakai A., Tadokoro K., Yanagisawa H., Nagafuchi S., Hoshikawa N., Suzuki T., Kohsaka T., Hasegawa T., Nakahori Y., Yamada M. A novel mutation of the WT1 gene (a tumor suppressor gene for Wilms tumor) in a patient with Denys-Drash syndrome. Hum Mol Genet 1993; 2: 1969–1970
   PubMed Web of Science ®Google Scholar
• Miwa H., Beran M., Saunders G.F. Expression of the Wilms tumor gene (WT1) in human leukemias. Leukemia 1992; 6: 405–409
   PubMed Web of Science ®Google Scholar
• Miyagi T., Ahuja H., Kubota T., Kubonishi I., Koeffler H.P., Miyoshi I. Expression of the candidate Wilms tumor gene, WT1, in human leukemia cells. Leukemia 1993; 7: 970–977
   PubMed Web of Science ®Google Scholar
• King-Underwood L., Renshaw J., Pritchard-Jones K. Mutations in the Wilms Tumor Gene WT1 in Leukemias. Blood 1996; 87: 2171–2179
   PubMed Web of Science ®Google Scholar
• Inoue K., Sugiyama H., Ogawa H., Nakagawa M., Yamagami T., Miwa H., Kita K., Hiraoka A., Masaoka T., Nasu K., Kyo T., Dohy H., Nakauchi H., Ishidate T., Akiyama T., Kishimoto T. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 1994; 84: 3071–3079
   PubMed Web of Science ®Google Scholar
• Brieger J., Weidmann E., Fenchel K., Mitrou P.S., Hoelzer D., Bergmann L. The expression of the Wilms tumor gene in acute myelocytic leukemias as a possible marker for leukemic blast cells. Leukemia 1994; 8: 2138–2143
   PubMed Web of Science ®Google Scholar
• Patmasiriwat P., Fraizer G.C., Claxton D., Kantarjian H., Saunders G.F. Expression pattern of WT1 and GATA-1 in AML with chromosome 16q22 abnormalities. Leukemia 1996; 10: 1127–1133
   PubMed Web of Science ®Google Scholar
• Pritchard-Jones K., Renshaw J., King-Underwood L. The Wilms tumour (WT1) gene is mutated in a secondary leukemia in a WAGR patient. Hum Mol Genet 1994; 3: 1633–1637
   PubMed Web of Science ®Google Scholar
• Fritsch G., Stimpfl M., Kurz M., Printz D., Buchinger P., Fischmeister G., Hoecker P., Gadner H. The composition of CD34 subpopulations differs between bone marrow, blood and cord blood. Bone-Marrow-Transplant 1996; 17: 169–178
   PubMed Web of Science ®Google Scholar
• Fraizer G.C., Patmasiriwat P., Zhang X., Saunders G.F. Expression of the tumor suppressor gene WT1 in both human and mouse bone marrow [letter]. Blood 1995; 86: 4704–4706
   PubMed Web of Science ®Google Scholar
• Hastie N.D. The genetics of Wilms tumor-a case of disrupted development. Annu Rev Genet 1994; 28: 523–558
   PubMed Web of Science ®Google Scholar
• Rodeck U., Bossier A., Kari C., Humphreys C.W., Gyorfi T., Maurer J., Thiel E., Menssen H.D. Expression of the WT1 Wilms tumor gene by normal and malignant human melanocytes. Int J Cancer 1994; 59: 78–82
   PubMed Web of Science ®Google Scholar
• Coppes M.J., Ye Y., Rackley R., Zhao X.L., Liefers G.J., Casey G., Williams B.R. Analysis of WT1 in granulosa cell and other sex cord-stromal tumors. Cancer Res 1993; 53: 2712–2714
   PubMed Web of Science ®Google Scholar
• Bruening W., Gros P., Sato T., Stanimir J., Nakamura Y., Housman D., Pelletier J. Analysis of the 11p13 Wilms tumor suppressor gene (WT1) in ovarian tumors. Cancel Invest 1993; 11: 393–399
   PubMed Web of Science ®Google Scholar
• Rackley R., Casey G., Zhao X.I., Miller D.W., Williams B.R.G., Coppes M.J. Analysis of the Wilms tumor suppressor gene WT1 in endometrial carcinoma. Genes Chromosomes and Cancer 1995; 14: 313–315
   PubMed Web of Science ®Google Scholar
• Quek H.H., Chow V.T., Tock E.P. The third zinc finger of the WT1 gene is mutated in Wilms tumour but not in a broad range of other urogenital tumours. Anticancer Res 1993; 13: 1575–1580
   PubMed Web of Science ®Google Scholar
• Park S., Schalling M., Bernard A., Maheswaran S., Shipley G.C., Roberts D., Fletcher J., Shipman R., Rheinwald J., Demetri G., Griffin J., Minden M., Housman D., Haber D. The Wilms tumour gene WT1 is expressed in murine mesoderm-derived tissues and mutated in a human mesothelioma. Nat Genet 1993; 4: 415–420
   PubMed Web of Science ®Google Scholar
• Langerak A.W., Williamson K.A., Miyagawa K., Hagemeijer A., Versnel M.A., Hastie N.D. Expression of the Wilms tumor gene WT1 in human malignant mesothelioma cell lines and relationship to platelet-derived growth factor A and insulin-like growth factor 2 expression. Genes Chromosom Cancer 1995; 12: 87–96
   PubMed Web of Science ®Google Scholar
• Brown K.W., Wilmore H.P., Watson J.E., Mott M.G., Berry P.J., Maitland N.J. Low frequency of mutations in the WT1 coding region in Wilms tumor. Genes Chromosom Cancer 1993; 8: 74–79
   PubMed Web of Science ®Google Scholar
• Gessler M., Konig A., Arden K., Grundy P., Orkin S., Sallan S., Peters C., Ruyle S., Mandell J., Li F., Cavenee W., Bruns G. Infrequent mutation of the WT1 gene in 77 Wilms Tumors. Hum Mutat 1994; 3: 212–222
   PubMed Web of Science ®Google Scholar
• Algar E., Blackburn D., Kromykh T., Taylor G., Smith P. Leukemia 1997; 11: 110–113
   PubMed Web of Science ®Google Scholar
• Rupprecht H.D., Drummond I.A., Madden S.L., Rauscher F.J., Sukhatme V.P. The Wilms tumor suppressor gene WT1 is negatively autoregulated. J Biol Chem 1994; 269: 6198–6206
   PubMed Web of Science ®Google Scholar
• Malik K.T., Poirier V., Wins S.M., Brown K.W. Autoregulation of the human WT1 gene promoter. Febs Lett 1994; 349: 75–78
   PubMed Web of Science ®Google Scholar
• Hunger S.P., Sklar J., Link M.P. Acute lymphoblastic leukemia occurring as a second malignant neoplasm in childhood: report of three cases and review of the literature. J Clin Oncol 1992; 10: 156–163
   PubMed Web of Science ®Google Scholar
• Moss T.J., Strauss L.C., Das L., Feig S.A. Secondary leukemia following successful treatment of Wilms tumor. Am J Pediatr Hematol Oncol 1989; 11: 158–161
   PubMedGoogle Scholar
• Perilongo G., Felix C.A., Meadows A.T., Nowell P., Biegel J., Lange B.J. Sequential development of Wilms tumor, T-cell acute lymphoblastic leukemia, medul-loblastoma and myeloid leukemia in a child with type 1 neurofibromatosis: A clinical and cytogenetic case report. Leukemia 1993; 7: 912–915
   PubMed Web of Science ®Google Scholar
• Hartley A.L., Birch J.M., Harris M., Blair V., Morris-Jones P.H., Gattamaneni H.R., Kelsey A.M. Leukemia, lymphoma, and related disorders in families of children diagnosed with Wilms tumor. Cancer Genet Cytogenet 1994; 77: 129–133
   PubMed Web of Science ®Google Scholar
• Orkin S.H. Transcription factors and hematopoietic development. J-Biol-Chem 1995; 270: 4955–4958
   PubMed Web of Science ®Google Scholar
• Haber D.A., Park S., Maheswaran S., Englert C., Re G.G., Hazen-Martin D.J., Sens D.A., Garvin A.J. WT1-mediated growth suppression of Wilms tumor cells expressing a WT1 splicing variant. Science 1993; 262: 2057–2059
   PubMed Web of Science ®Google Scholar
• Luo X.N., Reddy J.C., Yeyati P.L., Idris A.H., Hosono S., Haber D.A., Licht J.D., Atweh G.F. The tumor suppressor gene WT1 inhibits ras-mediated transformation. Oncogene 1995; 11: 743–750
   PubMed Web of Science ®Google Scholar
• Haber D.A., Buckler A.J., Glaser T., Call K.M., Pelletier J., Sohn R.L., Douglass E.C., Housman D.E. An internal deletion within an 11p13 zinc finger gene contributes to the development of Wilms tumor. Cell 1990; 61: 1257–1269
   PubMed Web of Science ®Google Scholar
• Haber D.A., Timmers H.T., Pelletier J., Sharp P.A., Housman D.E. A dominant mutation in the Wilms tumor gene WT1 cooperates with the viral oncogene El A in transformation of primary kidney cells. Proc Natl Acad Sci U S A 1992; 89: 6010–6014
   PubMed Web of Science ®Google Scholar
• Reddy J.C., Morris J.C., Wang J., English M.A., Haber D.A., Shi Y., Licht J.D. WT1-mediated transcriptional activation is inhibited by dominant negative mutant proteins. J Biol Chem 1995; 270: 10878–10884
   PubMed Web of Science ®Google Scholar
• Maheswaran S., Park S., Bernard A., Morris J.F., Rauscher F.J., Hill D.E., Haber D.A. Physical and functional interaction between WT1 and p53 proteins. Proc Natl Acad Sci USA 1993; 90: 5100–5104
   PubMed Web of Science ®Google Scholar
• Maheswaran S., Englert C., Bennett P., Heinrich G., Haber D.A. The WT1 gene product stabilizes p53 and inhibits p53-mediated apoptosis. Genes-Dev 1995; 9: 2143–2156
   PubMed Web of Science ®Google Scholar
• Little M., Holmes G., Bickmore W., Van Heyningen V., Hastie N., Wainwright B. DNA binding capacity of the WT1 protein is abolished by Denys-Drash syndrome point mutations. Hum Mol Genet 1995; 4: 351–358
   PubMed Web of Science ®Google Scholar
• Little M.H., Williamson K.A., Mannens M., Kelsey A., Gosden C., Hastie N.D., Van-Heyningen V. Evidence that WT1 mutations in Denys-Drash syndrome patients may act in a dominant-negative fashion. Hum Mol Genet 1993; 2: 259–264
   PubMed Web of Science ®Google Scholar
• Schneider S., Wildhardt G., Ludwig R., Royer-Pokora B. Exon skipping due to a mutation in a donor splice site in the WT-1 gene is associated with Wilms tumor and severe genital malformations. Hum Genet 1993; 91: 599–604
   PubMed Web of Science ®Google Scholar
• Baird P.N., Santos A., Groves N., Jadresic L., Cowell J.K. Constitutional mutations in the WT1 gene in patients with Denys-Drash syndrome. Hum Mol Genet 1992; 1: 301–305
   PubMedGoogle Scholar
• Wang Z.Y., Qiu Q.Q., Gurrieri M., Huang J., Deuel T.F. WT1, the Wilms tumor suppressor gene product, represses transcription through an interactive nuclear protein. Oncogene 1995; 10: 1243–1247
   PubMed Web of Science ®Google Scholar
• Moffett P., Bruening W., Nakagama H., Bardeesy N., Housman D., Housman D.E., Pelletier J. Antagonism of WT1 activity by protein self-association. Proc Natl Acad Sci U S A 1995; 92: 11105–11109
   PubMed Web of Science ®Google Scholar
• Varanasi R., Bardeesy N., Ghahremani M., Petruzzi M.J., Nowak N., Adam M.A., Grundy P., Shows T.B., Pelletier J. Fine structure analysis of the WT1 gene in sporadic Wilms tumors. Proc Natl Acad Sci USA 1994; 91: 3554–3558
   PubMed Web of Science ®Google Scholar
• Little M.H., Prosser J., Condie A., Smith P.J., Van-Heyningen V., Hastie N.D. Zinc finger point mutations within the WT1 gene in Wilms tumor patients. Proc Natl Acad Sci U S A 1992; 89: 4791–1795
   PubMed Web of Science ®Google Scholar
• Simms L.A., Algar E.M., Smith P.J. Splicing of exon 5 in the WT1 gene is disrupted in Wilms tumour. Eur-J-Cancer 1995; 31A: 2270–2276
   PubMed Web of Science ®Google Scholar
• Pritchard-Jones K. Mutations in the Wilms tumour gene WT1: what do they mean. Eur J Cancer 1995; 31A: 2138–2140
   PubMed Web of Science ®Google Scholar
• Englert C., Vidal M., Maheswaran S., Ge Y., Ezzell R.M., Isselbacher K.J., Haber D.A. Truncated WT1 mutants alter the subnuclear localization of the wild-type protein. Proc Natl Acad Sci U S A 1995; 92: 11960–11964
   PubMed Web of Science ®Google Scholar
• Valcarcel J., Singh R., Zamore P.D., Green M.R. The protein Sex-lethal antagonizes the splicing factor U2AF to regulate alternative splicing of transformer pre-mRNA. Nature 1993; 362: 171–175
   PubMed Web of Science ®Google Scholar
• Sakamoto H., Inoue K., Higuchi I., Ono Y., Shimura Y. Control of Drosophila Sex-lethal pre-mRNA splicing by its own female-specific product. Nucleic Acids Res 1992; 20: 5533–5540
   PubMed Web of Science ®Google Scholar
• Drummond I.A., Madden S.L., Rohwer-Nutter P., Bell G.I., Sukhatme V.P., Rauscher F.J. Repression of the insulin-like growth factor II gene by the Wilms tumor suppressor WT1. Science 1992; 257: 674–678
   PubMed Web of Science ®Google Scholar
• Harrington M.A., Konicek B., Song A., Xia X.L., Fredericks W.J., Rauscher F.J. Inhibition of colony-stimulating factor-1 promoter activity by the product of the Wilms tumor locus. J Biol Chem 1993; 268: 21271–21275
   PubMed Web of Science ®Google Scholar
• Wang Z.Y., Madden S.L., Deuel T.F., Rauscher F.J. The Wilms tumor gene product, WT1, represses transcription of the platelet-derived growth factor A-chain gene. J Biol Chem 1992; 267: 21999–20002
   PubMed Web of Science ®Google Scholar
• Werner H., Re G.G., Drummond I.A., Sukhatme V.P., Rauscher F.J., Sens D.A., Garvin A.J., LeRoith D., Roberts C., Jr. Increased expression of the insulin-like growth factor I receptor gene, IGF1R, in Wilms tumor is correlated with modulation of IGF1R promoter activity by the WT1 Wilms tumor gene product. Proc Natl Acad Sci U S A 1993; 90: 5828–5832
   PubMed Web of Science ®Google Scholar
• Ryan G., Steele-Perkins V., Morris J.F., Rauscher F.J., Dressler G.R. Repression of Pax-2 by WT1 during normal kidney development. Development 1995; 121: 867–875
   PubMed Web of Science ®Google Scholar
• Goodyer P., Dehbi M., Torban E., Bruening W., Pelletier J. Repression of the retinoic acid receptor-alpha gene by the Wilms tumor suppressor gene product. WT1, Oncogene 1995; 10: 1125–1129
   PubMed Web of Science ®Google Scholar
• Hewitt S.M., Hamada S., McDonnell T.J., Rauscher F.J., Saunders G.F. Regulation of the proto-oncogenes bcl-2 and c-myc by the Wilms tumor suppressor gene WT1. Cancer-Res 1995; 55: 5386–5389
   PubMed Web of Science ®Google Scholar
• Englert C., Hou X., Maheswaran S., Bennett P., Ngwu C., Re G.G., Garvin A.J., Rosner M.R., Haber D.A. WT1 suppresses synthesis of the epidermal growth factor receptor and induces apoptosis. EMBO-J 1995; 14: 4662–4675
   PubMed Web of Science ®Google Scholar
• Reddy J.C., Hosono S., Licht J.D. The transcriptional effect of WT1 is modulated by choice of expression vector. J-Biol-Chem 1995; 270: 29976–29982
   PubMed Web of Science ®Google Scholar
• Reddy J.C., Licht J.D. The WT1 Wilms tumor suppressor gene: how much do we really know. Biochim-Biophys-Acta 1996; 1287: 1–28
   PubMed Web of Science ®Google Scholar
• Wang Z.Y., Qiu Q.Q., Huang J., Gurrieri M., Deuel T.F. Products of alternatively spliced transcripts of the Wilms tumor suppressor gene, WTI, have altered DNA binding specificity and regulate transcription in different ways. Oncogene 1995; 10: 415–422
   PubMed Web of Science ®Google Scholar
• Nichols K.E., Re G.G., Yan Y.X., Garvin A.J., Haber D.A. WT1 induces expression of insulin-like growth factor 2 in Wilms tumor cells. Cancer-Res 1995; 55: 4540–4543
   PubMed Web of Science ®Google Scholar
• Cook D., Hinkes M., Bernfield M., Rauscher F.J. Transcriptional activation of the syndecan-1 promoter by the Wilms tumor protein WT1. Oncogene 1996; 13: 1789–1799
   PubMed Web of Science ®Google Scholar
• Werner H., Shen Orr Z., Rauscher F.J., Morris J.F., Roberts C.T., Jr., Le Roith D. Inhibition of cellular proliferation by the Wilms tumor suppressor WT1 is associated with suppression of insulin-like growth factor I receptor gene expression. Mol Cell Biol 1995; 15: 3516–3522
   PubMed Web of Science ®Google Scholar
• Martinerie C., Chevalier G., Rauscher F.J., Perbal B. Regulation of nov by WT1: a potential role for nov in nephrogenesis. Oncogene 1996; 12: 1479–1492
   PubMed Web of Science ®Google Scholar
• Reiss K., Porcu P., Sell C., Pietrzkowski Z., Baserga R. The insulin-like growth factor 1 receptor is required for the proliferation of hemopoietic cells. Oncogene 1992; 7: 2243–2248
   PubMed Web of Science ®Google Scholar
• Collins S.J., Robertson K.A., Mueller L. Retinoic acid-induced granulocytic differentiation of HL-60 myeloid leukemia cells is mediated directly through the retinoic acid receptor (RAR-alpha). Mol-Cell-Biol 1990; 10: 2154–2163
   Web of Science ®Google Scholar
• Merino R., Ding L., Veis D.J., Korsmeyer S.J., Nunez G. Developmental regulation of the Bcl-2 protein and susceptibility to cell death in B-lymphocytes. EMBO-J 1994; 13: 683–691
   PubMed Web of Science ®Google Scholar
• Bensi L., Longo R., Vecchi A., Messora C., Garagnani L., Bernardi S., Tamassia M.G., Sacchi S. Bcl-2 oncoprotein expression in acute myeloid leukemia. Haematologica 1995; 80: 98–102
   PubMed Web of Science ®Google Scholar
• Rackley R.R., Flenniken A.M., Kuriyan N.P., Kessler P.M., Stoler M.H., Williams B.R. Expression of the Wilms tumor suppressor gene WT1 during mouse embryo-genesis. Cell Growth Differ 1993; 4: 1023–1031
   PubMedGoogle Scholar
• Armstrong J.F., Pritchard-Jones K., Bickmore W.A., Hastie N.D., Bard J.B. The expression of the Wilms tumour gene, WT1, in the developing mammalian embryo. Mech Dev 1993; 40: 85–97
   PubMed Web of Science ®Google Scholar
• Medvinsky A., Dzierzak E. Definitive hematopoiesis is autonomously initiated by the AGM region. Cell 1996; 86: 897–906
   PubMed Web of Science ®Google Scholar
• Fraizer G.C., Wu Y.J., Hewitt S.M., Maity T., Ton C.C., Huff V., Saunders G.F. Transcriptional regulation of the human Wilms tumor gene (WT1). Cell type-specific enhancer and promiscuous promoter. J Biol Chem 1994; 269: 8892–8900
   PubMed Web of Science ®Google Scholar
• Zhang X., Fraizer G., Saunders G. Two hematopoietic specific enhancers of the WT1 gene function in different cell lineages. Blood 1995; 86, Abst. no. 2980
   Web of Science ®Google Scholar
• Wu Y., Fraizer G.C., Saunders G.F. GATA-1 transactivates the WT1 hematopoietic specific enhancer. J Biol Chem 1995; 270: 5944–5949
   PubMed Web of Science ®Google Scholar
• Renshaw J., King-Underwood L., Pritchard-Jones K. Differential splicing of the Wilms tumour (WT1) gene in haemopoietic and genitourinary tissues. Proc. AACR 1996; 37: 529
   Google Scholar
• Hewitt S.M., Saunders G.F. Differentially spliced exon 5 of the Wilms tumor gene WT1 modifies gene function. Anticancer-Res 1996; 16: 621–626
   PubMed Web of Science ®Google Scholar
• Kudoh T., Ishidate T., Moriyama M., Toyoshima K., Akiyama T. Gl phase arrest induced by Wilms tumor protein WT1 is abrogated by cyclin/CDK complexes. Proc Natl Acad Sci USA 1995; 92: 4517–4521
   PubMed Web of Science ®Google Scholar
• Yamagami T., Sugiyama H., Inoue K., Ogawa H., Tatekawa T., Hirata M., Kudoh T., Akiyama T., Murakami A., Maekawa T. Growth inhibition of human leukemic cells by WT1 (Wilms tumor gene) antisense oligodeoxynucleotides: implications for the involvement of WT1 in leukemogenesis. Blood 1996; 87: 2878–2884
   PubMed Web of Science ®Google Scholar
• Algar E.M., Khromykh T., Smith S.I., Blackburn D.M., Bryson G.J., Smith P.J. A WT1 antisense oligonucleotide inhibits proliferation and induces apoptosis in myeloid leukemia cell lines. Oncogene 1996; 12: 1005–1014
   PubMed Web of Science ®Google Scholar
• Lassus P., Ferlin M., Piette J., Hibner U. Anti-apoptotic activity of low levels of wild type p53. EMBO J 1996; 15: 4566–4573
   PubMed Web of Science ®Google Scholar
• Weinberg R.A. E2F and cell proliferation: a world turned upside down. Cell 1996; 85: 457–459
   PubMed Web of Science ®Google Scholar